Auris Medical Holding AG Announces Patient Recruitment for Phase 3 Clinical Trial of Tinnitus Drug is Complete

Keyzilen® is a small molecule N-methyl-D-aspartate (NMDA) receptor antagonistin that is in development for treatment of acute tinnitus of the inner ear.